Skip to content

Population Pharmacokinetics of Intravenous Caffeine Citrate for Prevention of Apnoea in Preterm Infants

Population Pharmacokinetics of Intravenous Caffeine Citrate for Prevention of Apnoea in Preterm Infants

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16007977
Enrollment
Unknown
Registered
2016-02-23
Start date
2016-03-28
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnoea of Newborn

Interventions

ONE: A loading dose of 20 mg/kg of caffeine citrate was administered intravenously over 30 min within 24 hours of birth
then patients were maintained on a dose of 5 mg/kg/day over 10 min. The maintenance dose should be adjusted to 10 mg/kg/day if apnoea occured. When necessary,adjust the dose based&#32

Sponsors

The Third Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The preterm infants younger than 37 weeks gestational age who received caffeine for the prevention of apnoea within 24 hours of birth; 2. at least one caffeine concentration; 3. agreed to sign informed consent.

Exclusion criteria

Exclusion criteria: Any congenital chromosomal abnormality, infection (sepsis con-firmed by blood culture), or neurologic condition were grounds for exclusion.

Design outcomes

Primary

MeasureTime frame
caffeine serum concentration;

Secondary

MeasureTime frame
Occurrence of (recurrent) apnoea;Acute drug side effects;

Countries

China

Contacts

Public ContactSitu Bing
843234573@qq.com+86 13922249029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026